Literature DB >> 18972201

Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.

Dharmawijaya N Lekamge1, Michelle Lane, Robert B Gilchrist, Kelton P Tremellen.   

Abstract

PURPOSE: This retrospective study was carried out to evaluate whether increasing the starting dose of FSH stimulation above the standard dose of 150 IU/day in patients with low predicted ovarian reserve can improve IVF outcomes.
METHOD: A total of 122 women aged less than 36 years in their first cycle of IVF were identified as having likely low ovarian reserve based on a serum AMH measurement below 14 pmol/l. Thirty five women were administered the standard dose of 150 IU/day FSH, while the remaining 87 received a higher starting dose (200-300 IU/day FSH). There were no significant differences in age, BMI, antral follicle count, serum AMH, FSH or aetiology of infertility between the two dose groups.
RESULTS: No significant improvement in oocyte and embryo yield or pregnancy rates was observed following an upward adjustment of FSH starting dose. While increasing the dose of FSH above 150 IU/day did not produce any adverse events such as OHSS, it did consume an extra 1,100 IU of FSH per IVF cycle.
CONCLUSION: The upward FSH dose adjustment in anticipation of low ovarian reserve can not be advocated as it is both expensive and of no proven clinical value.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972201      PMCID: PMC2593769          DOI: 10.1007/s10815-008-9266-6

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  39 in total

1.  Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve.

Authors:  I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

2.  A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.

Authors:  Eric H M Hoomans; Bernard B Mulder
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

3.  Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation.

Authors:  Wouter J K Hehenkamp; Caspar W N Looman; Axel P N Themmen; Frank H de Jong; E R Te Velde; Frank J M Broekmans
Journal:  J Clin Endocrinol Metab       Date:  2006-06-27       Impact factor: 5.958

4.  Antimüllerian hormone serum levels: a putative marker for ovarian aging.

Authors:  Annemarie de Vet; Joop S E Laven; Frank H de Jong; Axel P N Themmen; Bart C J M Fauser
Journal:  Fertil Steril       Date:  2002-02       Impact factor: 7.329

5.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

6.  A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram.

Authors:  B Popovic-Todorovic; A Loft; A Lindhard; S Bangsbøll; A M Andersson; A Nyboe Andersen
Journal:  Hum Reprod       Date:  2003-04       Impact factor: 6.918

7.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

8.  Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility.

Authors:  Vinay Sharma; Victoria Allgar; M Rajkhowa
Journal:  Fertil Steril       Date:  2002-07       Impact factor: 7.329

9.  A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.

Authors:  Peter Y K Yong; Sandra Brett; David T Baird; K J Thong
Journal:  Fertil Steril       Date:  2003-02       Impact factor: 7.329

10.  A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment.

Authors:  B Popovic-Todorovic; A Loft; H Ejdrup Bredkjaeer; S Bangsbøll; I K Nielsen; A Nyboe Andersen
Journal:  Hum Reprod       Date:  2003-11       Impact factor: 6.918

View more
  17 in total

1.  Prolonged gonadotropin stimulation is associated with decreased ART success.

Authors:  Meleen Chuang; Athena Zapantis; Martina Taylor; Sangita K Jindal; Genevieve S Neal-Perry; Harry J Lieman; Alex Joel Polotsky
Journal:  J Assist Reprod Genet       Date:  2010-09-07       Impact factor: 3.412

2.  Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer?

Authors:  Sanghoon Lee; Kutluk Oktay
Journal:  Fertil Steril       Date:  2012-07-06       Impact factor: 7.329

3.  Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles.

Authors:  Valerie L Baker; Morton B Brown; Barbara Luke; George W Smith; James J Ireland
Journal:  Fertil Steril       Date:  2015-08-18       Impact factor: 7.329

4.  Defining ovarian reserve to better understand ovarian aging.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2011-02-07       Impact factor: 5.211

5.  Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.

Authors:  Cheng-Hsuan Wu; Yu-Ching Chen; Hsin-Hung Wu; Jyuer-Ger Yang; Yu-Jun Chang; Horng-Der Tsai
Journal:  J Assist Reprod Genet       Date:  2009-07       Impact factor: 3.412

6.  "Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial.

Authors:  Alberto Revelli; Alessandra Chiadò; Paola Dalmasso; Veronica Stabile; Francesca Evangelista; Gemma Basso; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2014-04-04       Impact factor: 3.412

Review 7.  Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).

Authors:  Human Fatemi; Wilma Bilger; Deborah Denis; Georg Griesinger; Antonio La Marca; Salvatore Longobardi; Mary Mahony; Xiaoyan Yin; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-05-11       Impact factor: 5.211

Review 8.  Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization.

Authors:  Alberto Revelli; Simona Casano; Francesca Salvagno; Luisa Delle Piane
Journal:  Reprod Biol Endocrinol       Date:  2011-02-16       Impact factor: 5.211

9.  FSH dose is negatively correlated with number of oocytes retrieved: analysis of a data set with ~650,000 ART cycles that previously identified an inverse relationship between FSH dose and live birth rate.

Authors:  Zaramasina L Clark; Mili Thakur; Richard E Leach; James J Ireland
Journal:  J Assist Reprod Genet       Date:  2021-04-08       Impact factor: 3.357

Review 10.  The effects of oxidative stress on female reproduction: a review.

Authors:  Ashok Agarwal; Anamar Aponte-Mellado; Beena J Premkumar; Amani Shaman; Sajal Gupta
Journal:  Reprod Biol Endocrinol       Date:  2012-06-29       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.